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Neurobiology of Disease

Amyloid-␤-Induced Pathological Behaviors Are Suppressed
by Ginkgo biloba Extract EGb 761 and Ginkgolides in
Transgenic Caenorhabditis elegans
Yanjue Wu,1 Zhixin Wu,2 Peter Butko,3 Yves Christen,4 Mary P. Lambert,5 William L. Klein,5 Christopher D. Link,6 and
Yuan Luo1
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, Departments of 2Biological Sciences
and 3Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi 39406, 4Ipsen, 75016 Paris, France, 5Department of
Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208, and 6Institute for Behavioral Genetics, University of Colorado, Boulder,
Colorado 80309

Amyloid-␤ (A␤) toxicity has been postulated to initiate synaptic loss and subsequent neuronal degeneration seen in Alzheimer’s disease
(AD). We previously demonstrated that the standardized Ginkgo biloba extract EGb 761, commonly used to enhance memory and by AD
patients for dementia, inhibits A␤-induced apoptosis in neuroblastoma cells. In this study, we use EGb 761 and its single constituents to
associate A␤ species with A␤-induced pathological behaviors in a model organism, Caenorhabditis elegans. We report that EGb 761 and
one of its components, ginkgolide A, alleviates A␤-induced pathological behaviors, including paralysis, and reduces chemotaxis behavior
and 5-HT hypersensitivity in a transgenic C. elegans. We also show that EGb 761 inhibits A␤ oligomerization and A␤ deposits in the
worms. Moreover, reducing oxidative stress is not the mechanism by which EGb 761 and ginkgolide A suppress A␤-induced paralysis
because the antioxidant L-ascorbic acid reduced intracellular levels of hydrogen peroxide to the same extent as EGb 761, but was not
nearly as effective in suppressing paralysis in the transgenic C. elegans. These findings suggest that (1) EGb 761 suppresses A␤-related
pathological behaviors, (2) the protection against A␤ toxicity by EGb 761 is mediated primarily by modulating A␤ oligomeric species, and
(3) ginkgolide A has therapeutic potential for prevention and treatment of AD.
Key words: A␤ peptide; Alzheimer’s disease; behavior; mutant; phenotype; serotonin

Introduction
Despite a widely accepted “amyloid cascade hypothesis” for Alzheimer’s disease (AD) (Hardy and Selkoe, 2002), the current explanation for amyloid-␤ (A␤) toxicity in AD still remains controversial in view of the fact that the relationship between A␤
species and A␤-specific behavior has not been defined in vivo
(Lorenzo and Yankner, 1994; Pike et al., 1995; Lambert et al.,
1998). A leading theory is that A␤ oligomers are responsible for
initiation of synaptic dysfunction, an early event that leads to
neurodegeneration observed in AD (Walsh and Selkoe, 2004;
Roselli et al., 2005; Lesne et al., 2006; Oddo et al., 2006). The
evidence for or against these hypotheses is critical for specific
therapeutic strategies. It has previously been demonstrated that
small molecules inhibiting A␤ oligomers also reduced its toxicity
(Walsh et al., 2005; Yang et al., 2005; Maezawa et al., 2006).
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However, most of these studies were conducted in vitro, and the
use of a transgenic mice model of AD for pharmacological evaluation and mechanistic studies is time-consuming. Simple invertebrate models of neurodegenerative diseases offer experimental
advantages for addressing basic cellular processes that are conserved among all animals (Link, 2005; Wu and Luo, 2005).
The standard Gingko biloba leaf extract EGb 761 has been
given routinely as a prescription drug in many countries, and as a
dietary supplement in the United States, for Alzheimer’s dementia (Christen and Maixent, 2002). Several clinical trials have provided evidence of efficacy (Le Bars et al., 1997; Birks et al., 2002;
Mix and Crews, 2002; Le Bars, 2003), comparable with Donepezil
(Mazza et al., 2006), as a symptomatic treatment of mild to moderate AD, and suggestive for AD prevention (Andrieu et al.,
2003). Currently, a National Institutes of Health-supported GEM
(Ginkgo Evaluation of Memory) study in the United States and a
GuidAge study in Europe are underway to evaluate EGb 761 as a
preventive drug (DeKosky et al., 2006). Substantial experimental
data indicate that EGb 761 has neuroprotective and neuromodulatory effects (Luo, 2001; Watanabe et al., 2001; Yao et al., 2001;
DeFeudis, 2002). Two of its major constituents, flavonoids (24%)
and terpenoids (6%), have been actively investigated for their
neuroprotective properties (DeFeudis, 1998; Smith and Luo,
2003). The ginkgolides, known as potent antagonists of platelet-
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Table 1. Description of the well characterized transgenic C. elegans used in the
study
Strains

Transgene

Expression

Phenotype

N2
CL4176
CL1175
CL2006
CL2355

myo-3/A␤1– 42
myo-3
unc-54/A␤1– 42
snb-1/A␤1– 42

Wild type
Inducible muscle A␤1– 42
Control for CL4176
Constitutive muscle A␤1– 42
Inducible neuronal A␤1– 42

CL2122
CL2179

mtl-2/GFP
myo-3/GFP

Control for CL2355
GFP control for CL4176

Wt movement
Rapid paralysis
Normal
Progressive paralysis
Reduced chemotaxis
Hypersensitive to 5-HT
Wt movement
Wt movement

Wt, Wild type.

Figure 1. Chemical structures of the ginkgolides (A), the bilobalide (B), and three flavonol
glycosides (C). The ginkgolides and bilobalide are specific to the G. biloba tree. Ginkgolides A, B,
C, J, and bilobalide, but not ginkgolide M, are constituents of EGb 761. The flavonol glycosides
quercetin, kaempferol, and isorhamnetin are present in trace amounts in EGb 761 (DeFeudis,
1998).

-activating factor receptor (PAFR) (Smith et al., 1996) are unique
to the G. biloba tree (Nakanishi, 1967; Ivic et al., 2003; Jaracz et al.,
2004). The flavonoids are involved in antioxidative properties of
EGb 761.
We and others previously described an inhibitory effect of
EGb 761 on A␤ oligomerization in solution (Luo et al., 2002;
Chromy et al., 2003) providing evidence that EGb 761 can alter
the biochemical and biophysical properties of A␤ that may underpin its toxicity. In the present study, we use the transgenic
Caenorhabditis elegans model (Link, 1995) that exhibits several
pathological behaviors to associate A␤ species with A␤-induced
abnormal behaviors in the organism. The current results support
the hypothesis that A␤ oligomers are the toxic species and suggest
that beneficial effects of EGb 761 on the cognitive function of AD
patients is, at least in part, attributable to its modulation of A␤
oligomerization.

Materials and Methods
G. biloba extract EGb 761 was provided by Schwabe Pharmaceuticals
(Karlsruhe, Germany); the extract is well characterized and is the one
used in the ongoing clinic trials. The flavonoid fraction (Fig. 1C) was
from Ipsen (Paris France). The individual constituents of EGb 761
ginkgolide A (GA), ginkgolide B (GB), ginkgolide C (GC), ginkgolide J
(GJ) (Fig. 1 A), and bilobalide (BB) (Fig. 1 B) were obtained from Dr. I. A.
Khan at the National Center for Natural Products Research (Oxford,
MS). Congo red (CR), L-ascorbic acid [vitamin C (VC)] as well as other
chemicals were from Sigma (St. Louis, MO). Stock solutions of all chemicals were made either with 100% ethanol or with distilled water only.
The final concentration of ethanol did not exceed 0.01% in the food
(Escherichia coli strain OP50). All chemicals for treatment of experimental animals were added directly to the OP50 food source and the working
concentration was equal to 100 g/ml for EGb 761, or 10 g/ml for single
constituents of EGb 761.
C. elegans strains. (For a summary, see Table 1.) The wild-type strain

N2 (Bristol) was from Caenorhabditis Genetics Center (University of
Minnesota, Minneapolis, MN). The construction and characterization of
the transgenic nematode strains CL2006 (unc-54/A␤1– 42) and CL4176
(smg-1 ts [myo-3/A␤1– 42 long 3⬘-untranslated region (UTR)]) and its
control strain CL1175 (smg-1 ts) have been described previously (Link,
1995; Link et al., 2001). The CL2006 strain constitutively produces a
body-wall muscle-specific A␤1– 42, whereas the expression of musclespecific A␤1– 42 in CL4176 depends on upshifting temperature from 16 to
23°C. The transgenic arrays in the CL2006, CL1175, and CL4176 strains
all contain the dominant rol-6(su1066 ) morphological marker. The
CL2355 strain [smg-1 ts (snb-1/A␤1– 42/long 3⬘-UTR)] employs the promoter of the C. elegans synaptobrevin ortholog (snb-1) to drive panneuronal expression of A␤1– 42, which is inducible by temperature upshift. The transgenic arrays in CL2355 and the control strain CL2122 are
marked with a mtl-2/green fluorescent protein (GFP) transgene that
causes constitutive intestinal GFP expression. An integrated myo-3/GFP/
long 3⬘-UTR strain (CL2179) is used as a control for CL4176. This strain
has a GFP reporter tagged to the same promoter as the transgenic strains
and has detectable GFP at 16°C, which is significantly stronger at higher
temperatures.
C. elegans maintenance and treatment. The wild-type (N2) and the
transgenic CL2006 were propagated at 20°C, CL4176 and CL2355 and
their controls at 16°C, on solid nematode growth medium (NGM)
seeded with 100 l spots of E. coli (OP50) for food. To prepare agesynchronized animals, nematodes were transferred to fresh NGM plates
on reaching reproductive maturity at 3 d of age and allowed to lay eggs for
4 – 6 h (overnight for Western blotting of CL4176 and CL2355). Isolated
hatchlings from the synchronized eggs (day 1) were cultured on fresh
NGM plates in either a 20°C or a 16°C (for CL4176, CL2355, and their
control strains) temperature-controlled incubator (model 2005; Sheldon
Manufacturing, Cornelius, OR). The worms were fed with the drugs
either from stage L1 (1 d of age) or starting from the egg.
Paralysis assays. The strain CL4176 (Drake et al., 2003; Link et al.,
2003) maintained at 16°C was egg-synchronized onto the 35 ⫻ 10 mm
culture plates containing either a vehicle or drug. Transgene expression
was induced by upshifting the temperature from 16 to 23°C, started at the
36th hour after egg laying and lasted until the end of the paralysis assay.
Paralysis was scored at 1 h intervals until the last worm became paralyzed.
Chemotaxis assays. Chemotaxis assays (see Fig. 3A) were performed as
described by Bargmann et al. (1993). Synchronized transgenic C. elegans
CL2355 and its control strain CL2122 were treated with or without 100
g/ml EGb 761, or 10 g/ml single components, starting from the egg.
They were cultured in 16°C for 36 h, and then in 23°C for another 36 h.
The worms were then collected, washed with M9 (Wood, 1988) three
times, and assayed in 100 mm plates containing 1.9% agar, 1 mM CaCl2,
1 mM MgSO4, and 25 mM phosphate buffer, pH 6.0. Twenty worms were
placed to the center of the plate. After all animals were transferred to the
center of the assay plate, 1 l of odorant (0.1% benzaldehyde in 100%
ethanol) (Sigma) along with 1 l of 1 M sodium azide were added to the
original spot. On the opposite side of the attractant, 1 l drop of sodium
azide and 1 l of control odorant (100% ethanol) were added. Assay
plates were incubated at 23°C for 1 h and chemotaxis index (CI) was
scored. Chemotaxis index is defined as follows: (number of worms at the
attractant location – number of worms at the control location)/total
number of worms on the plate.
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5-HT sensitivity assay. Synchronized transgenic worms (CL2355) and the control strain
(CL2122) fed with or without the drugs were
collected at 36 h after temperature upshift. Serotonin (creatinine sulfate salt; Sigma) was dissolved in M9 buffer to 1 mM. Twenty worms in
each group were washed with M9 buffer for
three times and transferred into 200 l serotonin solution in a 96-well assay plate. Worms
were scored after 5 min as active or paralyzed
(nonmotile for 5 s).
Western blotting of A␤ species. The A␤ species
in the transgenic C. elegans strains was identified by immunoblotting using a Tris-Tricine gel
and the standard Western blotting protocol except that the polyvinylidene difluoride membranes were boiled for 5 min after the transfer.
After the experimental treatments, the worms
were collected by washing with distilled water,
quickly frozen in liquid nitrogen, sonicated in
the cell lysis buffer (50 mM HEPES, pH 7.5, 6
mM MgCl2, 1 mM EDTA, 75 mM sucrose, 25 mM
benzamide, 1 mM DTT, 1% Triton X-100), and
heated with sample buffer containing 5%
␤-mercaptoethanol (1:1; Bio-Rad, Hercules,
CA). To detect A␤ oligomers, samples were extracted in PBS containing proteinase inhibitor
mixture (Sigma) with (for antibody A11) or
without 2% SDS (for antibody NU-4). After
mixing with the sample buffer, proteins were
unheated and loaded on the gel. Equal amounts
of the total protein (80 g) were loaded in each
lane. Antibody to A␤1–17 (6E10; at 1:500 dilutions) was from Signet (Dedham, MA). Antibody selective against oligomers (A-11; at
1:1000 dilution) was from Biosource (Camarillo, CA) (Kayed et al., 2003). Antibody specific
to A␤ oligomers (NU4; 1:3000) was generated
in W. L. Klein’s laboratory (Lambert, 2006).
Anti-mouse IgG or anti-rabbit IgG (1:5000;
Signet) was used as the secondary antibody. The
mean densities of the A␤ bands were analyzed
by a gel documentation system (Alpha Innotech
801054; Imgen Technologies, Alexandria, VA).
Fluorescence staining of A␤ deposits. Individ- Figure 2. Effect of EGb 761 and its constituents on A␤-induced paralysis in muscle A␤ strain CL4176. A, Representative images
ual CL2006 transgenic nematodes were fixed in of A␤-induced paralysis in the transgenic CL4176 strain without transgene expression (no A␤), untreated with EGb 761 (Ctrl; left
4% paraformaldehyde/PBS, pH 7.4, for 24 h panel), and in the transgenic CL4176 strain (muscle A␤ strain) fed with (EGb; right) or without EGb 761 (Ctrl; middle) at 36 h after
at 4°C, and permeabilized in 5% fresh temperature upshift. B, Time course of paralysis assays in CL4176 fed with different drugs. Synchronized eggs of CL4176 C. elegans
␤-mercaptoethanol, 1% Triton X-100, 125 mM were maintained at 16°C, on the 35 ⫻ 10 mm culture plates (⬃35 eggs/plate) containing vehicle (Ctrl), EGb 761 (100 g/ml), or
Tris, pH 7.4, in a 37°C incubator for 24 h. The CR (139 g/ml). The hatched worms were grown for 38 h at 16°C followed by upshifting the temperature to 23°C to induce the
nematodes were stained with 0.125% thioflavin transgene expression. The paralysis was scored at 60 min intervals. Data are expressed as percentage of nonparalyzed worms from
S (Sigma) in 50% ethanol for 2 min, destained, at least three independent assays of 100 worms in each experiment. Paralysis in the transgenic strain CL4176 is attributable to A␤
and mounted on slides for microscopy. Fluores- expression compared with the control strain CL1175, which does not express A␤ transgene (filled triangles). C, Time course of
cence images were acquired at the same exposure paralysis assay in CL4176 worms fed with ginkgolide A or J (10 g/ml for each). Paralysis was scored at 30 min intervals. Data were
parameters using a 40⫻ objective of the micro- obtained from three different experiments with 100 worms in each group. Error bars indicate SEM. D, An illustrative diagram
scope (BX 60; Olympus, Tokyo, Japan) equipped indicating the time duration of temperature upshift for expressing A␤ transgene, onset of paralysis, detectable A␤, and EGb
with a digital camera (Micropublisher 5.0; QIm- protective effect at different treatment regimens.
aging, Burnaby, British Columbia, Canada). The
into wells of 96-well plates. DCF-DA (final concentration, 50 M in PBS)
number of thioflavin S-reactive deposits in the area anterior of the pharynwas added to each well at 37°C for quantification of fluorescence in an
geal bulb in individual animals was scored.
FLx800 Microplate Fluorescence Reader (Bio-Tek Instruments, WiH2O2 assay in C. elegans. Intracellular ROS were measured in C. elnooski, VT) with the excitation at 485 nm and emission at 530 nm.
egans using 2,7-dichlorofluorescein diacetate (DCF-DA) (Invitrogen,
Samples were read every 20 min for 2.5 h.
Eugene, OR) as described previously (Smith and Luo, 2003). AgeStatistical analyses. Differences between untreated and drug-treated
synchronized C. elegans were collected at 36 h after temperature upshift
groups were analyzed for statistical significance by independent Stu(CL4176/1175) into 100 l of PBS with 1% Tween 20 (PBST) in Eppendent’s t test of two groups using Origin 6.0 software (Microcal Software,
dorf tubes in groups of 40 worms. The worms were then subjected to
Northampton, MA). A value of p ⬍ 0.05 is considered statistically signifequally timed homogenization (Pellet Pestle Motor; MG Scientific,
icant. Correlation analysis was performed with the GraphPad (San DiPleasant Prairie, WI) and sonication (Branson Sonifier 250; VWR Scienego, CA) Prism 4.0a, using a one-tailed Pearson test.
tific, Suwanee, GA) to break up the outer cuticle. Samples were collected
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Table 2. Quantitative analysis of paralysis
Experiments

PT50

Control
EGb 761
Ascorbic acid
Congo red
Control
Ginkgolide A
Ginkgolide B
Ginkgolide C
Ginkgolide J
Bilobalide B
Flavonoids

5.7 ⫾ 0.8
9.4 ⫾ 1.3*
3.4 ⫾ 0.3
7.5 ⫾ 0.8
3.5 ⫾ 0.3
7.2 ⫾ 0.3**
2.8 ⫾ 0.4
3.5 ⫾ 0.3
6.8 ⫾ 0.6*
2.8 ⫾ 0.4
2.7 ⫾ 0.6

p value
0.03
0.17
0.15
0.001
0.18
1.00
0.01
0.18
0.24

The paralysis assays were quantified for mean time duration at which 50% worms were paralyzed (PT50) from the
transgenic worms fed with or without the drugs. Values of p were obtained from nine independent assays for the
worms fed with EGb 761 or Congo red, each paired with untreated controls, and from three assays for L -ascorbic acid,
and single components paired with the control.

Results

EGb 761, ginkgolide A and J alleviate A␤-induced paralysis in
the transgenic C. elegans
To determine whether EGb 761 specifically protects against A␤induced toxicity in vivo, we first fed EGb 761 to a transgenic C.
elegans line, in which expression of human A␤ peptide in the
muscle cells induces an A␤-dependent paralysis phenotype in the
worms (muscle A␤ strain, CL4176) (Link et al., 2003). Synchronized eggs from transgenic worms, or control worms were placed
on OP50 food containing vehicle or EGb 761 (100 g/ml) for 36 h
at 16°C, followed by temperature upshift from 16 to 23°C to
induce transgene expression. Figure 2 A is a set of photographs
representing the following: the transgenic muscle A␤ expression
strain (CL4176) without the temperature upshift and untreated
with EGb 761 [control (Ctrl), no A␤] (Fig. 2 A, left panel), the
temperature upshifted (for 36 h) CL4176, untreated with EGb
761 (Ctrl, muscle A␤) (Fig. 2〈, middle panel), or treated with
EGb 761 (EGb, muscle A␤) (Fig. 2 A, right panel). Worms that
did not move or only moved the head, under a gentle touch with
a platinum loop were scored as paralyzed. In Figure 2 A, the shape
of movement and tracks left on the food (indicated with black
lines) in nonparalyzed worms are obvious. The arrowheads indicate paralyzed worms (straight line shape), and the arrows indicate the moving worms (the “C” or “S” shape). At 36 h, ⬃100%
worms without the transgene expression were nonparalyzed (Fig.
2 A, left). At this time, only ⬃20% A␤ transgene expressing
worms without EGb feeding were nonparalyzed (Fig. 2 A, middle), and ⬃60% transgene expressing worms fed with EGb were
nonparalyzed (Fig. 2 A, right). Note the tracks left behind on the
plate in the EGb 761-fed C. elegans (Fig. 2 A, right panel).
Figure 2 B is a time course of paralysis in the C. elegans CL4176
fed with a vehicle (0.01% ethanol; open circles), EGb 761 (EGb,
100 g/ml; filled circles), or CR (139 g/ml; filled squares) from
day 1 till after the temperature upshift for 36 h. CL1175 (filled
triangles) is a transgenic control strain that does not express A␤.
A notable delay of paralysis was observed in the transgenic worms
fed with EGb 761 compared with the untreated controls. Congo
red also moderately delayed paralysis. Interestingly, the worms
fed with 100 g/ml L-ascorbic acid, a known antioxidant, did not
show any delay in paralysis (for clarity of the graph, data are
presented only in Table 2). To further determine which constituent(s) of EGb 761 contributed to reducing A␤-induced paralysis, transgenic C. elegans CL4176 were fed with GA, GB, GC, GJ,
BB, and a flavonoid (Flav) fraction (10 g/ml each). Among
individual components tested, only GA and GJ exhibited signifi-

cant delay of A␤-induced paralysis (for clarity, the paralysis time
courses for other components are not shown in Fig. 2C) (for
statistical analysis, see Table 1). Reproducibility of paralysis at a
given temperature in individual trials was consistent. Because the
transgene product is temperature sensitive, the onset of paralysis
is related to the specific value of room temperature, at which the
paralysis assays were conducted. Thus, the variation in the onset
of paralysis between Figure 2, B and C, is attributed to the slight
difference in room temperature on the days when the assays were
performed (22 vs 23°C). Nevertheless, the difference between the
worms fed with and without EGb 761 was consistently significant
at both 22 and 23°C.
For quantitative analysis, we define PT50 as the time interval,
from the onset of paralysis, at which 50% of the worms were
paralyzed (i.e., PT50 of 5.7 h for control was obtained by subtracting the onset time of paralysis 27 h from the time when 50% of the
worms were paralyzed at 32.7 h) (Table 1). A statistically significant delay of A␤-induced paralysis was observed in the worms fed
with EGb 761 (Table 2) (control vs EGb, p ⫽ 0.03; n ⫽ 9 assays; 40
worms in each assay group), but not in Congo red-treated animals (control vs CR, p ⫽ 0.15; n ⫽ 9 assays; 30 worms in each
assay group). Among six single components of EGb 761, only
ginkgolides A and J exhibited a statistically significant delay of
paralysis (control vs GA, p ⫽ 0.001; control vs GJ, p ⫽ 0.01; n ⫽
3 assays; 30 worms in each assay group). Moreover, EGb 761
feeding was found to delay paralysis through a wide range of
concentrations (10 –500 g/ml) (data not shown). Paralysis was
not delayed in the worms fed with EGb 761 before A␤ induction,
at the time of A␤ induction, or after A␤ induction by temperature
upshift (data not shown) (see diagram in Fig. 2 D), suggesting
that short duration of feeding may not be sufficient to alleviate
the A␤ toxicity.
EGb 761 suppresses neuronal A␤ expression-induced defect
in chemotaxis behavior and 5-HT sensitivity
The paralysis phenotype in muscle of the A␤ expression strain
CL4176, used above, has been established and used to illustrate
several important molecular processes related to A␤ toxicity
(Drake et al., 2003; Link et al., 2003). To relate A␤ toxicity with
neurological functions, we characterized a behavior phenotype of
the transgenic strain in which A␤ was expressed in the neuronal
cells (CL2355). Two characteristic neuronal controlled behaviors, chemotaxis and 5-HT sensitivity, were assayed in these
worms. The chemotaxis response in C. elegans is mediated by
activation of several sensory neurons and interneurons to stimulate the motor neurons (Hobert, 2003). The CI is a measure of the
fraction of worms that are able to arrive at the location of the
attractants (Matsuura et al., 2005). To investigate the effect of
EGb 761 on the performance of chemotaxis behavior, we applied
the chemical benzaldehyde as an attractant and ethanol as a control, both containing sodium azide, which paralyzes the worms
on contact (Fig. 3A). The chemotaxis index was scored in the
transgenic strain and the control strain at day 4 of age. Figure 3B
shows that the transgenic mutant CL2355 exhibits a significant
reduction of CI compared with the control strain CL2122, or no
A␤ strain untreated (Ctrl CIno A␤, 0.36 ⫾ 0.02 vs Ctrl CIA␤, 0.27 ⫾
0.02; n ⫽ 4; p ⫽ 0.01). EGb 761 feeding of the control strain had
no effect on their CI (Ctrl CIno A␤, 0.36 ⫾ 0.02, vs EGb CIno A␤,
0.35 ⫾ 0.04; n ⫽ 4; p ⫽ 0.31), but it significantly normalizes the
reduced CI in the neuronal A␤ transgenic strain (Ctrl CIA␤,
0.27 ⫾ 0.02, vs EGb CIA␤, 0.37 ⫾ 0.03; n ⫽ 4; p ⫽ 0.01; a total of
240 worms was used in each assay). A similar effect was observed
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in the transgenic worms fed with GA (Ctrl CIA␤, 0.27 ⫾ 0.02, vs
GA CIA␤, 0.34 ⫾ 0.01; n ⫽ 4; p ⫽ 0.03).
Taking advantage of the ability of C. elegans to take up exogenous 5-HT (Sawin et al., 2000), we conducted a serotonin (5HT) hypersensitivity assay to further determine whether 5-HTmediated neurotransmission is affected by expressing A␤
transgene in the neurons. 5-HT is a key neurotransmitter that
modulates several behaviors of C. elegans, including egg laying,
locomotion, and olfactory learning (Schafer and Kenyon, 1995;
Sawin et al., 2000; Nuttley et al., 2002; Zhang et al., 2005). When
exogenous 5-HT is applied to the nematodes, they become paralyzed as a result of the sensitivity to excessive 5-HT. This 5-HT
sensitivity assay has previously been used to identify 5-HT hypersensitive mutants, which revealed the functional relationship of
the genes involved in 5-HT signaling (Schafer et al., 1996; Ranganathan et al., 2001). We used this assay to test the response to
5-HT in the transgenic mutant CL2355 in comparison with the
control strain CL2122. Twenty animals from each strain were
placed in 200 l of 5-HT solution (1 mM) in 96-well microtiter
wells. Paralysis was scored at 5 min after exposure to 5-HT. Figure
3C demonstrates that the transgenic neuronal line CL2355 untreated (Ctrl) was particularly sensitive to 5-HT, compared with
the transgenic control CL2122 (no A␤ strain) untreated (percentage of CtrlCL2355, 35.9 ⫾ 7.8%, vs percentage of CtrlCL2122, 73.2 ⫾
3.3; n ⫽ 3; p ⬍ 0.001). The neuronal A␤ worms (CL2355) then
were fed with EGb 761 or its single components. Only feeding
with EGb 761 (EGb vs Ctrl, 69.5 ⫾ 4.9%, vs 35.9 ⫾ 7.8%; n ⫽ 3;
p ⫽ 0.003) and ginkgolide A (GA vs Ctrl, 65.5 ⫾ 4.0, vs 35.9 ⫾
7.8%; n ⫽ 3; p ⫽ 0.005) significantly normalized the defective
response to 5-HT in the transgenic strain. Neither the antioxidant
L-ascorbic acid (VC), kaempferol, the flavonoid fraction of EGb
761 (KA), or CR normalized the paralysis in the neuronal A␤
strain CL2355.
Among behavior assays available to examine neuronal toxicity
(including egg laying, body bend, pharyngeal pumping, locomotion/swimming, and paralysis), the serotonin sensitivity assay
(swimming) was performed to determine a behavior phenotype
in neuronal A␤-expressing strain for the following reasons: (1)
early work by Horvitz et al. (1982) demonstrated that exogenous
5-HT affected the wild-type C. elegans locomotion, or swimming
behavior. Subsequently, it was reported that the effect was
blocked in the MOD-1 mutant (a 5-HT-gated chloride channel)
(Ranganathan et al., 2000), suggesting that this assay measures a
5-HT-mediated response; (2) in C. elegans, the experiencedependent behavior (an enhanced slowing of the response) is
modulated by 5-HT (Sawin et al., 2000), which provides a link
between the behavior plasticity and the neuronal plasticity associated with the impairment of cognitive function observed in AD;
(3) among others, this phenotype exhibited the most significant
difference between the control strain (CL2122) and the transgenic strain (CL2355). Thus, the A␤-dependent behavior may
provide the opportunity to elucidate 5-HT-mediated neuroprotection against A␤ neurotoxicity.
EGb 761 modulates A␤ oligomers in the transgenic C. elegans
To determine whether inhibition of A␤ oligomerization by EGb
761 underpins its mechanism for suppressing pathological behaviors in C. elegans, we analyzed A␤ species from the transgenic
C. elegans fed with or without EGb 761 by Western blotting using
antibodies against A␤ (6E10) or specific against A␤ oligomers
(A-11 and NU-4). Figure 4 A shows A␤-immunoreactive (6E10)
bands (Mr, ⬃7.2–28 kDa) detected in the tissues from the transgenic worms (CL4176) fed with or without EGb 761 and the
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Figure 3. Assays for chemotaxis behavior and serotonin sensitivity in neuronal A␤expressing strain CL2355. A, Schematic diagram of the chemotaxis assay. Synchronized L4
worms treated with or without drugs (20 worms for each assay) were placed in the center of an
assay plate (100 ⫻ 15 mm) containing 1 l of attractant (0.1% benzaldelhyde) plus 1 l of
1 M sodium azide at the edge of the plate on one side (black dot), and 1 l of control odorant
(100% ethanol, *) plus 1 l of 1 M sodium azide on the opposite edge of the plate (star). After 1 h
incubation at room temperature, CI was scored as follows: CI ⫽ (number of worms at attractant ⫺ number of worms at control)/total number of worms. In each experiment, at least 60
worms from each group were analyzed. B, Chemotaxis behavior in neuronal strain CL2355
(neuronal A␤ strain) was reduced compared with the transgenic control strain CL2122 (no A␤
strain). Feeding with 100 g/ml EGb 761 for 4 d alleviated this descent in the transgenic strain,
but not in the control strains (n ⫽ 4; *p ⬍ 0.05). Error bars indicate SEM. C, Serotonin hypersensitivity in neuronal-expressing A␤ strain (CL2355) is normalized by EGb 761 and its constituents. Strain CL2355 were fed with EGb 761 (100 g/ml), vehicle (Ctrl; 100 g/ml), ginkgolides (GA, GB, GC, GJ) (10 g/ml each), BB (10 g/ml), quercetin (QC) (10 g/ml), kaempferol
(KA; 10 g/ml) L-ascorbic acid (VC) (100 g/ml), and CR (139 g/ml) for 4 d. The worms were
collected at 36 h after temperature upshift to 23°C. 5-HT sensitivity assay was conducted in
96-well plate containing 200 l of 1 mM 5-HT solution. Percentage of active worms is calculated
as follows: number of the active worms (after placed into serotonin solution for 5 min and still
kept moving for 5 s)/total worms. A total of 60 worms of each group was used for each time
(n ⫽ 3; **p ⬍ 0.01).
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observation in CL4176, a similar inhibitory effect by EGb 761 was observed in the
transgenic strain CL2006. In this strain,
EGb 761 inhibited the same A␤ species
and, at the same time, increased A␤ monomers in the same tissue extract (data not
shown). In contrast, L-ascorbic acid (VC)
(100 g/ml for 72 h) did not inhibit the A␤
oligomerization or increase the monomer
content as EGb 761 did, in the transgenic
worm CL4176 (Fig. 4 A, lane 4). CR (139
g/ml) inhibited the oligomerization to a
lesser degree than EGb 761 but also failed
to increase the A␤ monomer content in
the same samples in the transgenic worms
(Fig. 4 A, CR, lane 5). The mean densities
of the A␤ oligomer band at ⬃20 kDa as
well as the A␤ monomer bands were analyzed. Statistically (Fig. 4 B), EGb 761 and
Congo red significantly reduced the oligomers (Fig. 4 B, solid bars) (n ⫽ 3; control
vs EGb, p ⫽ 0.04; Ctrl vs CR, p ⫽ 0.02).
Most importantly, only EGb 761 significantly increased the A␤ monomers from
the same C. elegans samples (Fig. 4 B,
dashed bars) (n ⫽ 3; control vs EGb, p ⫽
0.01).
Neuroprotection by EGb 761 is known
as a “multipotent” action (i.e., it is
achieved by modulating a variety of biological pathways simultaneously because
of its complex nature) (DeFeudis, 2002;
Smith and Luo, 2003). We next asked
whether the inhibitory effect on oligomerization by an individual constituent is sufficient to correlate with its alleviative effect
on A␤-induced paralysis. The transgenic
C. elegans was fed with different single
constituents and A␤ species were analyzed
by Western blotting using antibody 6E10.
Figure 4. A␤ species in the transgenic C. elegans. A, Representative Western blot (BL) of A␤ species in the transgenic C. elegans
CL4176 fed with or without EGb 761 (EGb), L-ascorbic acid (VC), and CR. The CL4176 worms maintained at 16°C were fed with a Figure 4C represents a noticeable shift of
vehicle (Ctrl), EGb 761 (100 g/ml), or L-ascorbic acid (100 g/ml), Congo red (139 g/ml) at day 1 of age for 72 h. The worms A␤ oligomer species to monomers by EGb
were collected, and equal amounts of protein were loaded on each gel lane and immunoblotted with an anti-A␤ antibody (6E10). 761 and ginkgolide A. Blots from three inThe arrow indicates changes of A␤ oligomers and the monomers in the worms after the treatment. B, Quantification of immu- dependent experiments were quantified in
noreactive A␤ oligomers (the bend at 20 kDa; filled bars) and A␤ monomers (dashed bars) by Gel Documentary System Fluochem Figure 4 D. It shows that EGb 761 (EGb),
SP (Alpha Innotech, San Leandro, CA). Data are expressed as mean density of an indicated band from three independent experi- GA, and GJ remarkably reduced the A␤
ments. Error bars represent SEM. *p ⬍ 0.05 C, A␤ species in transgenic C. elegans CL4176 fed with or without EGb 761 (100 oligomers band (filled bars) (Ctrl vs EGb,
g/ml), GA, GB, GC, GJ, BB, and a flavonol diglycosides quercetin (QC) (10 g/ml for each component). A␤ oligomers (top) and **p ⫽ 0.006; Ctrl vs GA, **p ⫽ 0.006; Ctrl
the protein loading control actin (bottom) are indicated. Note that immunoreactive A␤ monomers (arrow on the right) are vs GJ, **p ⫽ 0.007). GB, GC, and GJ also
enhanced in worms fed with GA. D, Quantification of immunoreactive A␤ oligomers (solid bars) and A␤ monomers (dashed bars)
significantly reduced this A␤ species, to
from three independent experiments. Error bars represent SEM. *p ⬍ 0.05; **p ⬍ 0.01; #p ⬍ 0.05 (4 kDa monomer). E,
Immunoblot using antibody A11 (anti-oligomers) in the C. elegans strains CL4176 fed with EGb 761 (100 g/ml) or vehicle (Ctrl) a somehow lesser degree (Ctrl vs GB,
for 4 d. The blot represents three independent experiments. F, Immunoblot using NU-4 (anti-A␤ oligomers) antibody in C. elegans *p ⫽ 0.04; Ctrl vs GC, *p ⫽ 0.04), comstrains CL4176 and CL2355 (-Tg) fed with EGb 761 (100 g/ml) or vehicle (Ctrl). The blot represents two independent experi- pared with untreated transgenic worms
ments. G, An integrated myo-3/GFP strain (CL2179), as a control for CL4176, was fed with (bottom panel) or without (top) EGb 761 (Ctrl). Only EGb 761 and GA signifiin the same way as CL4176 in A. GFP fluorescence was examined at 36 h after temperature upshift, under a 20⫻ objective on the cantly enhanced the A␤ monomers
fluorescence microscope (E800; Nikon). The images were processed by IPLab software 3.7 (Scanalytics, Fairfax, VA). No difference (dashed bars) (Ctrl vs EGb, #p ⫽ 0.02;
in GFP fluorescence density and intensity were observed in the two groups.
Ctrl vs GA, #p ⫽ 0.03).
To confirm the properties of the A␤
comparison chemicals. Two immunoreactive A␤ species with
species modulated by EGb 761, we used two independent antimolecular weights at ⬃20 and 28 kDa were significantly debodies A11 (Fig. 4 E) and NU4 (Fig. 4 F). Antibody A11 is selective
creased in the worms fed with EGb 761 (100 g/ml for 72 h) (Fig.
for high molecular weight A␤ oligomers as well as other oligo4 A, EGb, lane 3). Interestingly, a simultaneous increase of the A␤
meric proteins (Kayed et al., 2003). This antibody was used to
monomers was observed in those worms. Consistent with the
reveal a temporal profile of A␤ oligomerization in mice model of
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AD (Oddo et al., 2006). Antibody NU-4 is a mice monoclonal
antibody generated in the W. L. Klein laboratory (Lambert,
2006), which is an improved version of the previously generated
low molecular weight oligomer [A␤-derived diffusible ligand
(ADDL)]-selective polyclonal rabbit antibody (M93/M94)
(Lambert et al., 2001). Levels of oligomers reactive to this antibody have been reported to be 70-fold higher in the AD patient’s
brain compared with the control brains (Gong et al., 2003). Prevention by EGb 761 of the oligomer formation in vitro was demonstrated using this antibody (Chromy et al., 2003).
Multiple immunoreactive bands were recognized by A11 in
the transgenic C. elegans CL4176 (Fig. 4 E, lane 2). Among these,
a major band at ⬃50 kDa disappeared in the CL4176 strain fed
with EGb 761 (Fig. 4 E, lane 3). The blot is representative of three
independent experiments. Because A11 also recognizes oligomeric structures other than A␤, we further performed the immunoblotting using an antibody specific to the toxic A␤ oligomers
referred to as ADDL (NU-4). Figure 4 F is representative of two
independent blots using antibody NU-4. An immunoreactive
band at 50 kDa, presumably a 12-mer species previously found to
be abundant in AD brain (Gong et al., 2003), was detected only in
the transgenic strain CL4176, but not in the transgenic control
strain. EGb 761 inhibited formation of this species completely
(Fig. 4 F, lane 3). EGb 761 also inhibited formation of higherorder A␤ species (⬃70 – 80 kDa, probably 16- to 18-mers) in the
neuronal strain CL2355. In addition, the A␤ species detected by
6E10 and A11/NU4 do not overlap, in terms of the size, which
suggests that multiple A␤ oligomers are attenuated by EGb 761.
The shift from larger A␤ oligomers to monomers caused by EGb
761 is striking, but it only can be detected by 6E10, because A11
and Nu-4 do not recognize monomeric A␤ (Chromy et al., 2003;
Lambert, 2006).
To determine whether EGb 761 affects the expression levels of
the A␤ transgene, rather than interacting with the A␤ peptide
species, an integrated myo-3/GFP strain (CL2179) with the same
promoter tagged with a GFP reporter was used as a control for
CL4176. To determine whether EGb 761 affects transcription of
the transgenes, the strain was handled the same way as CL4176, in
terms of temperature upshift regimen and EGb 761 feeding. Figure 4G shows that comparing the worms (CL2179) fed with or
without EGb, there is no visible difference in GFP fluorescence
density and intensity in the two groups, suggesting that EGb 761
feeding does not affect the levels of A␤ transgene expression in
the worms. Data from a microarray of the transgenic worms fed
with or without EGb 761 further supported this observation (data
not shown).
EGb 761 inhibits amyloid deposits in transgenic C. elegans
To decide whether the inhibitory effect of EGb 761 on A␤ oligomerization would affect amyloid formation, the number of
amyloid deposits was scored in the worm head region, which is
separated from the rest of the body by the pharyngeal bulb (black
arrows). Figure 5A shows A␤ deposits (black arrowheads) detected in the transgenic C. elegans (CL2006) (Fig. 5Ac) but not the
wild type (N2) (Fig. 5Ab), as previously observed (Link, 1995).
The number of A␤ deposits per nematode was reduced in the
transgenic C. elegans CL2006 fed with EGb 761 (Fig. 5Ad). The
worms exhibit background fluorescence without thioflavin S
staining (Fig. 5Aa), which provides a guide to define the head area
in the animals. Figure 5B shows that the mean number of A␤
deposits, from 24 worms in each group, was significantly reduced
in worms fed with 100 g/ml EGb 761 (Ctrl, 7.7 ⫾ 0.5, vs EGb,
4.9 ⫾ 0.6; n ⫽ 24; p ⫽ 0.002) or with 200 M Congo red (Ctrl,
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Figure 5. A␤ deposits in transgenic C. elegans CL2006 fed with or without drugs. A, Representative images of background fluorescence in a C. elegans without staining (a), with thioflavin S staining in the wild type (b), or in the transgenic strain CL2006 fed with (d) or without EGb
761 (c). Synchronized CL2006 worms were maintained at 20°C on NGM agar plates seeded with
E. coli as the food source. The worms were fed with EGb 761 or Congo red for 2 d starting at day
4 of age. At the end of the treatment, the nematodes were fixed in 4% paraformaldehyde,
permeabilized, and then stained with 0.125% thioflavin S. ␤-Amyloid deposits were examined
using a fluorescence microscope attached to a digital camera. The numbers of deposits (arrowheads) were scored in the worm head, which is separated from the body by pharyngeal bulb
(arrows). B, Quantitative analysis of ␤-amyloid deposits in the transgenic C. elegans CL2006 fed
with different chemicals for 48 h (EGb 761, 100 g/ml; the flavonoid fraction of EGb 761, 100
g/ml; Congo red, 139 g/ml). The quantity is expressed as mean number of ␤-amyloid
deposits/anterior area of the worm (n ⫽ 24 for each analysis). Error bars indicate SEM.
*p ⬍ 0.05; **p ⬍ 0.01.

6.2 ⫾ 0.8, vs CR, 5.5 ⫾ 1.1; n ⫽ 24; p ⫽ 0.025), but not with the
flavonoid fraction of EGb 761 (Ctrl, 7.1 ⫾ 0.9, vs Flav, 6.9 ⫾ 1.0;
n ⫽ 24; p ⬎ 0.05). These results suggest that EGb 761 inhibits A␤
oligomerization, which leads to an increase in the nontoxic A␤
monomers and the reduced amyloid deposits. Congo red, which
binds to A␤ fibrils, also reduced the A␤ deposits in C. elegans.
Levels of H2O2 in the transgenic C. elegans fed with EGb 761
and other chemicals
Given that numerous lines of evidence have associated oxidative
stress with AD and A␤ toxicity, we hypothesized that the antioxidative properties also contribute to the protective effects of EGb
761 against A␤ toxicity. We first tested the levels of H2O2 in the
transgenic control strain (CL1175) and the transgenic muscle A␤
strain (CL4176). Figure 6 A demonstrates that the untreated
transgenic strain CL4176 (Ctrl) exhibits increased levels of H2O2
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Three concentrations of EGb 761 (25, 50, and 100 g/ml) were
added to the transgenic C. elegans diet from day 1 of age until the
end of the temperature upshift. Feeding EGb 761 attenuated the
intracellular levels of H2O2 in a dose-dependent manner (Fig.
6 A). Feeding 100 g/ml EGb 761 exhibited most significant
reduction (Ctrl, 100 ⫾ 23%; EGb, 42 ⫾ 7%; n ⫽ 6; p ⫽ 0.04).
Interestingly, no significant reduction was observed in the
control worms fed with EGb 761 (Fig. 6 A), suggesting that the
effect of EGb 761 on attenuating H2O2 may be specific to A␤
expression. In comparison, 50 g/ml L-ascorbic acid (VC)
(Ctrl, 100 ⫾ 3%; VC, 31 ⫾ 3%; n ⫽ 3, p ⫽ 0.04), but not CR
(139 g/ml) (Ctrl, 100 ⫾ 3%; CR, 101 ⫾ 18%; n ⫽ 3; p ⫽ 0.11;
total of 300 worms in each group), also showed significant
attenuation of the A␤-induced elevation of H2O2. Among
single components of EGb 761 tested (10 g/ml for each),
only ginkgolide A significantly attenuated the levels of H2O2
( p ⫽ 0.047) (Fig. 6C).
Paralysis is associated with A␤ oligomers but not the level
of H2O2
To determine whether there is a correlative association between
the behavioral rescue and the decrease in A␤ oligomers by EGb
761 and its constituents, correlation analysis was performed.
Figure 7A shows a clear correlation between the amount of A␤
oligomers (mean density) and paralysis (PT50), with a value of
the Pearson correlation coefficient r of 0.566 ( p ⫽ 0.044).
Among all of the compounds, GJ, GA, and EGb 761 appear to
contribute the most to the correlation, in contrast with GC,
GB, and BB. The latter three compounds decrease the A␤
oligomers density without improving the worms’ paralysis.
Figure 7B is a plot of paralysis (PT50) versus levels of H2O2
measured by DCF fluorescence (see Materials and Methods).
Paralysis is dissociated from the level of reactive oxygen species (ROS), because no correlation of the paralysis with the
levels of H2O2 was found. The value of the Pearson correlation
coefficient r was 0.27 ( p ⫽ 0.07).
As summarized in Table 3, chemotaxis behavior does not correlate with the mean density of the A␤ oligomers. It is possible
that the chemosensory neural circuits are less sensitive to the A␤
toxicity, and thus the chemotaxis behavior may not be the best
assay for the latter. However, the serotonin hypersensitivity and
paralysis correlate well with the A␤ oligomers density, supporting
our hypothesis that EGb 761 and its constituents alleviate the
behavioral abnormalities by decreasing the levels of the toxic A␤
oligomers.
Figure 6. Levels of ROS in transgenic C. elegans. A, Levels of H2O2 in the C. elegans fed with
different concentration of EGb 761 (0, 25, 50, 100 g/ml). Age-synchronized groups of transgenic C. elegans strain CL4176 and the control strain CL1175 maintained at 16°C for 38 h were
temperature upshifted to 23°C for 38 h followed by the DCF assay for H2O2 described in Materials
and Methods. Statistical significance is observed in the worms fed with 100 g/ml EGb 761 (25
g/ml, p ⫽ 0.13; 50 g/ml, p ⫽ 0.09; 100 g/ml, p ⫽ 0.03; n ⫽ 3; total of 120 worms in
each group). B, Levels of H2O2 in CL4176 worms fed with vehicle (Ctrl), EGb 761 (EGb), L-ascorbic
acid (VC), or CR from 1 d of age until 3 d of age. C, Levels of H2O2 in the C. elegans fed with
different constituents of EGb 761 (ginkgolides GA, GB, GC, GJ). At least 60 animals from each
group were analyzed for the levels of H2O2. Results are expressed as percentage of fluorescence
(%DCF) relative to vehicle-treated controls, which is set as 100%. Statistical significance is
represented as follows: *p ⬍ 0.05; **p ⬍ 0.01. Error bars indicate SEM.

compared with the control strain (CL1175) that does not express
A␤ (no A␤ strain, p ⫽ 0.001). Next, we asked whether feeding
EGb 761 to the worms before the induction of A␤ expression
would prevent the elevation of H2O2 levels in the strain CL4176.

Discussion
In the present experiments, we sought to associate A␤ species
with A␤-specific pathological behaviors using transgenic C. elegans as a model and EGb 761 as a pharmacological modulator.
We found that EGb 761 alleviated A␤-induced paralysis, chemotaxis dysfunction, and 5-HT hypersensitivity in the transgenic C.
elegans expressing A␤. EGb 761 also modulated A␤ oligomers
and attenuated levels of H2O2 in the transgenic C. elegans
(CL4176). Interestingly, suppression of paralysis is associated
with inhibition of A␤ oligomerization but is disassociated with
the antioxidative effect (Fig. 7 A, B), suggesting that protective
effects of EGb 761 against A␤ toxicity is mediated primarily by
inhibition of A␤ oligomerization. If a similar mechanism is
shared with other species, it may represent a rationale for the
beneficial effects of EGb 761 in humans with AD-related dementia (Le Bars et al., 2000; Mazza et al., 2006) and for the enhanced
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EGb 761 and ginkgolide A on A␤ toxicity is specific for the following reasons.

Figure 7. Correlation analysis between paralysis (PT50 ) and 20 kDa A␤ oligomers (A) or with
levels of H2O2 (B). Correlation analysis was performed with the GraphPad Prism 4.0a, using a
one-tailed Pearson test. The linear regression line along with the 95% confidence interval is
shown only for illustrative purposes.
Table 3. Summary of correlation analysis
Behavior

Pearson r value

p value

Correlation with
A␤ oligomers

Paralysis
5-HT sensitivity
Chemotaxis

⫺0.566
⫺0.644
⫺0.451

0.044
0.043
0.131

Yes
Yes
No

The data are from 10 different drugs tested in three behavior assays. Correlation of paralysis (PT50), chemotaxis (CI),
and 5-HT sensitivity with the 20 kDa A␤ oligomers mean density was tested by Pearson’s test (see Materials and
Methods).

cognitive function by EGb 761 in the transgenic mice model of
AD (Tg2576) (Stackman et al., 2003).
EGb 761 has been known as an antioxidant that protects neuronal cells against amyloid toxicity in the cells (Bastianetto et al.,
2000; Yao et al., 2001). We demonstrate here that EGb 761 and
ginkgolide A suppress both A␤ oligomerization and A␤-induced
paralysis in a model organism, in a manner that does not parallel
the effects of known antioxidants. We believe that the effect of

EGb 761 modulates A␤ specific pathological behaviors
(Figs. 2, 3)
C. elegans is an ideal model organism for functional analysis of the
age-associated neurodegeneration because of its available genetic
information as well as the simple structure of its nervous system,
which consist of only 302 neurons in an adult nematode. We took
advantage of an established relationship between onset of A␤
expression and paralysis phenotype in a transgenic C. elegans
model (Link, 1995). The absence of endogenous A␤ production
in the worms offers an opportunity to find a direct role of the A␤
involvement in pathological behaviors (Wu and Luo, 2005). In
addition, predominantly intracellular expression of A␤ provides
another tool to address specific role of intracellular A␤ in relation
to its toxicity (Gutierrez-Zepeda and Luo, 2004). Substantial evidence implicates intracellular A␤ oligomers in early events related to AD (Kienlen-Campard et al., 2002).
For the first time, two neuronal behavior phenotypes were
characterized in a neuronal A␤-expressing strain CL2355. Both
chemotaxis and 5-HT signaling phenotypes are biologically relevant to A␤-induced toxicity. C. elegans uses six primary sensory
neurons to respond to ⬎40 different attractants and repellents
(Bargmann et al., 1993). The reinforcement is mediated by 5-HT
signaling in the worms (Zhang et al., 2005). Several possible
mechanisms could explain the 5-HT hypersensitive phenotype of
the A␤ transgene, including the following: (1) response to 5-HT,
which is modulated by calcium channel-dependent calcium influx (Schafer and Kenyon, 1995), was affected by the transgene
A␤ expression (Ingram, 2005); (2) reduced acetylcholine (ACh)
by A␤ accumulation in the worms; ACh is a negative regulator of
5-HT sensitivity in C. elegans (Schafer et al., 1996); and (3) A␤
may directly or indirectly block 5-HT reuptake in the worms. The
pathological behavior assays used here are simple and relatively
reproducible compared with other behavior assays in the worms.
Whether this form of pathological behavior uses molecular
mechanisms common to higher animals remains to be determined. A similar approach has recently revealed polyglutamine
threshold toxicity in a transgenic C. elegans model of Huntington’s disease (Brignull et al., 2006).
EGb 761 and ginkgolide A inhibit A␤ oligomerization
(Fig. 4A–D)
Accumulation of A␤ oligomers seems to be one of the earliest
events in the transgenic mice of AD (Oddo et al., 2006), which
impairs long-term potentiation (LTP) and memory (Walsh et
al., 2005; Lesne et al., 2006) and which correlates better with
severity of dementia in AD patients than the density of amyloid plaques (Gong et al., 2003). Some oligomers (⬃20 kDa)
inhibited by EGb 761 and ginkgolide A, as observed in this
study (Fig. 4 A–D), might be similar to, or identical with the
neurotoxic ADDLs, or A␤-derived diffusible ligands (Lambert
et al., 1998). Previous studies showed that EGb 761 could
inhibit formation of these species in solution (Luo et al., 2002;
Chromy et al., 2003). The higher-order A␤ oligomers (⬃50
kDa) inhibited by EGb 761 in the worms (Fig. 4 E, F ) might be
relevant to the species previously reported to be abundant in
the AD brain (Gong et al., 2003). Our results suggest, but do
not prove, that all of the oligomeric A␤ species inhibited by
EGb 761 and ginkgolide A are toxic.
Based on in vitro studies, a linear pathway leading from A␤
monomers via paranuclei, oligomers, to protofibrils, and then
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to fibrils was proposed (Bitan et al., 2003; Urbanc et al., 2004).
This pathway may provide an explanation for our observation
that Congo red, although it reduced A␤ deposits (Fig. 5B), did
not significantly delay A␤-induced paralysis (Fig. 2 B). We
speculate that EGb 761 and Congo red may bind to A␤ oligomers differently. For example, EGb 761 may have a higher
affinity for certain oligomeric species, whereas Congo red favors the fibril form of A␤. Thus, Congo red probably enters
the linear process of fibrillogenesis at later stages than EGb
761, which would still lead to reduced overall A␤ oligomers
(Fig. 4 A) and decreased A␤ deposits (Fig. 5B), but not the
appearance of A␤ monomers or significant suppression of
paralysis (Fig. 2 B) in the transgenic C. elegans. This theory
agrees with the previous observation that paralysis occurs before
detectable ␤-amyloid deposition in C. elegans (Drake et al., 2003).
Therefore, the paralysis suppression by EGb 761 and ginkgolide A
might be a consequence of the shift from the toxic A␤ oligomer to
the nontoxic A␤ monomers (Fig. 4A). Given its “multipotent” nature, it is also possible that EGb 761 differentially modulates different
processes of oligomerization.
The unique structure of ginkgolide A provides a rationale for
its specific effect
It is believed that the unique biological properties of ginkgolides arise from their unique “cage skeleton” structure. This
structure may share a common motif with Congo red and/or
curcumin (Yang et al., 2005), which all display affinity for
amyloidogenic conformations. It is not surprising that, among
all ginkgolides, only GA exhibited a correlation between reducing paralysis (Fig. 2C) and inhibiting A␤ oligomers (Fig.
4C,D). Biological effects of ginkgolides can markedly vary with
minor differences in their chemical structure. For example,
the presence of one extra hydroxyl group at position 7 converts GB, a potent PAFR antagonist (Ki ⫽ 0.88 M) into GC, a
constituent with much lower activity (Ki ⫽ 12.6 M)
(Vogensen et al., 2003). Indeed, GA and GJ are the components of the extract that inhibit or even eliminate the deadly
effects of A␤ on LTP (Nakanishi, 2005). GB affects hippocampal LTP by inhibiting the PAFR (Kondratskaya et al., 2004).
Given that very little is known about which components of
EGb 761 are the most efficacious, additional analyses of specific molecular structures of ginkgolides and of their interactions with A␤ may reveal novel compound(s) to protect
against AD.
The fact that the antioxidant L-ascorbic acid lowered the
levels of H2O2 (Fig. 6 B), but did not inhibit A␤ oligomerization (Fig. 4 A–C) nor suppressed paralysis (Table 2), suggests
that a mechanism(s) other than the relief from antioxidative
stress is operative in the ginkgolide-mediated protection
against A␤ toxicity in C. elegans. This finding is consistent
with the in vitro observation that no correlation exists between
relative potencies of polyphenols in inhibiting A␤ fibrils formation and in their oxidative features (Ono and Yamada,
2006). However, the dissociation of antioxidative effect from
delaying paralysis does not rule out the contribution of oxidative damage in A␤-dependent abnormal behaviors. Recent reports demonstrate that A␤-induced, and a pro-aggregationprotein-induced paralysis in transgenic C. elegans were
reduced by slowing aging (Cohen et al., 2006), or by coexpression of a stress response protein, the small heat shock protein
16 (sHSP-16) (Link et al., 2006) in the worms, respectively.
EGb 761 attenuated the expression of sHSP-16 protein in the
wild-type worms exposed to oxidative stress (Strayer et al.,
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2003). A possible explanation is that EGb 761 might act in a
manner similar to that of sHSP-16 in protecting against the
deleterious process, which would lead to a decreased need for
sHSP-16 expression. The antioxidative action of EGb 761 (Fig.
6 B) may contribute to the beneficial effect in AD (Zandi et al.,
2004), without being manifested in C. elegans.
Together, the neuroprotective effects of EGb 761 and ginkgolides on transgenic C. elegans behaviors provide strong evidence
that formation of intracellular A␤1– 42 oligomers is directly associated with A␤ toxicity, supporting the view that the A␤ oligomers are the toxic species in AD (Kayed et al., 2003; Walsh and
Selkoe, 2004). It is likely that the sequence of events manifested in
the behavior of the transgenic worms, as well as the pharmacological efficacy, share the similar mechanisms with the cognitive
impairment in mammals.
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